Rate of incident MACE per 100 patient years by average achieved on-treatment LDL-D levels in patients with ASCVD with and without comorbidities in a pooled analysis of alirocumab Phase 3a trials.
Supplementary material for the clinical efficacy and safety of Sodium-glucose Co-transporter 2 (SGLT2) inhibitors in patients with acute myocardial infarction; a meta-analysis of randomized control
ObjectiveThis study aimed to assess the adjunctive efficacy and safety of Puerarin injection (PI) on acute heart failure (AHF) based on a systematic review and meta-analysis. MethodsNine databases wer
Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism
Levosimendan, an inotrope, is widely used in the management of heart failure (HF) and cardiac surgery, but it remains uncertain whether levosimendan can improve renal function in patients with left ve
Background: This study aims to explore the role of low-dose rivaroxaban (≤10 mg daily) for the treatment of atherosclerotic cardiovascular disease (ASCVD). Methods: PubMed, Embase and the Cochrane Lib
